EU MDR Transition Ends for SaMD Exports: learn how Chinese SaMD suppliers can protect EU market access with Annex XVI clinical evaluation and GDPR-ready product design.

Medical device investment Europe in 2026 is shifting toward regulation-ready, workflow-fit medtech. Explore key risks, return drivers, and market signals investors cannot ignore.

EU MDR Annex XVI brings Mild HBOT Systems into Class IIa, raising CE marking, Notified Body, and UDI requirements. See what manufacturers and exporters must do now.

Translumenal robots manufacturer evaluation starts with clinical readiness. Learn how to assess evidence, workflow fit, sterilization, software reliability, and regulatory strength before buying.